[Adjunctive immunotherapy of mycobacterial infections].
Tomioka
Haruaki
H
Department of Microbiology and Immunology, Shimane University, School of Medicine, Izumo, Shimane, Japan.
Sato
Katsumasa
K
Shimizu
Toshiaki
T
Sano
Chiaki
C
D000255:Adenosine Triphosphate / Q000502:physiology / Q000627:therapeutic use; D000634:Aminoquinolines / Q000627:therapeutic use; D001428:Bacterial Vaccines / Q000627:therapeutic use; D016207:Cytokines / Q000037:antagonists & inhibitors / Q000502:physiology / Q000627:therapeutic use; D004365:Drugs, Chinese Herbal / Q000627:therapeutic use; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use*; D007167:Immunotherapy / Q000379:methods*; D009164:Mycobacterium Infections / Q000628:therapy*; D009363:Neoplasm Proteins / Q000627:therapeutic use; D008517:Phytotherapy; D010848:Picolinic Acids / Q000627:therapeutic use; D047889:Receptors, Tumor Necrosis Factor, Type II; D018417:Th1 Cells; D053319:Tumor Necrosis Factor Decoy Receptors
D000634:Aminoquinolines; D001428:Bacterial Vaccines; D016207:Cytokines; D004365:Drugs, Chinese Herbal; D007155:Immunologic Factors; D009363:Neoplasm Proteins; D010848:Picolinic Acids; D047889:Receptors, Tumor Necrosis Factor, Type II; D053319:Tumor Necrosis Factor Decoy Receptors; C119422:mao-bushi-saishin-to; C451081:SRL172; D000255:Adenosine Triphosphate; C030614:picolinic acid